Medtronic is recalling some of its implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT-D) devices because of an unexpected and rapid decrease in battery life. The company said this is due to a short circuit and will cause some devices to produce a “Recommended Replacement Time” (first warning that the battery is low) earlier than expected. Some devices may progress from “Recommended Replacement Time” to full battery depletion within as little as one day.

April 12, 2021 — Medtronic is recalling some of its implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT-D) devices because of an unexpected and rapid decrease in battery life.

Controversies and Advances in the Treatment of Cardiovascular Disease

Controversies & Advances in the Treatment of Cardiovascular Disease: The Twentieth in the Series, December 2-3, 2021, at the Maybourne Beverly Hills, Beverly Hills, California

 

Cardiovascular Interventions

32nd Annual Cardiovascular Interventions, November 16-19, 2021, at the Hilton La Jolla Torrey Pines, La Jolla, California

 

 

April 8, 2021 — Abbott today announced it has received European CE mark and Health Canada authorization this week for its next-generation TriClip Transcatheter Tricuspid Valve Repair (TTVR) System, a minimally invasive tricuspid heart valve repair device to treat tricuspid regurgitation (TR).

April 7, 2021 — Philips Healthcare announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Philips SmartCT application software, which is a component of Philips Azurion Image Guided Therapy System.

April 7, 2021 — Stereotaxis announced that Broward Health Medical Center is establishing a robotic electrophysiology (EP) program to expand access to advanced minimally-invasive treatment of heart rhythm disorders in Florida.

April 6, 2021 — A tsunami of chronic health conditions as a result of the COVID-19 (SARS-CoV-2) pandemic, especially cardiometabolic disease, may produce an enormous wave of death and disability that demands immediate, comprehensive strategies. In addition, COVID-19 has disrupted cardiovascular science and medicine, yet it presents opportunities to transform and create novel approaches that can yield new successes.

April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual anti-platelet therapy (DAPT) for patients with high bleeding risk (HBR). DAPT can be as short as 28 days, the shortest indication available in the world.

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter Investigational Device Exemption (IDE) clinical trial. This trial is expected to enroll up to 150 subjects in leading centers globally and will evaluate the safety and efficacy of the AcQBlate Force sensing ablation catheter and system in the treatment of right atrial typical flutter. 

In the U.S., right atrial typical flutter ablation procedures currently account for approximately 30% of cardiac ablations and are expected to reach 200,000 annually by 2025.[1]

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now